As of Apr 17
| +1.42 / +2.24%|
The 22 analysts offering 12-month price forecasts for Teva Pharmaceutical have a median target of 68.00, with a high estimate of 100.00 and a low estimate of 51.00. The median estimate represents a +4.76% increase from the last price of 64.91.
The current consensus among 27 polled investment analysts is to Buy stock in Teva Pharmaceutical. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.